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a  b  s  t  r  a  c  t
Intravesical botulinum toxin A (BoNTA) injection has been widely used for the treatment of
detrusor overactivity in patients with neurogenic bladder due to spinal cord injury who  do
not  respond to conventional treatment. There is no consensus about antibiotic prophylaxis
for  this procedure. We conducted a retrospective analysis of medical records of adult patients
with spinal cord injury who underwent detrusor BoNTA injection between January of 2007
and  December of 2013 in a rehabilitation hospital. Occurrence of symptomatic urinary tract
infection (UTI) was assessed in 3 groups in accordance with their use of antibiotics (pro-
phylactic dosage, 3 days, more than 3 days) for the treatment of asymptomatic bacteriuria.
All patients were performing self or assisted clean intermittent bladder catheterization and
underwent a rigid cystoscopy, under general or regional anesthesia with sedation, and the
drug  used was Botox®. A total of 616 procedures were performed during the study period.
There were 11 identiﬁed cases of UTI (1.8%) with a trend to a higher rate in the group that
used  antibiotics for longer time. This report shows that a single dose of antibiotics before
the  detrusor BoNTA injection is enough to prevent UTI. Randomized clinical trial should beconducted for deﬁnitive conclusions.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open  access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
the growing problem of bacterial resistance, the discussionntimicrobial prophylaxis is the systemic administration of
ntibiotics before or during surgery with the intent of reduc-
ng the risk of local or systemic infection after the procedure.
he potential beneﬁt of antimicrobial prophylaxis is deter-
ined by factors inherent to the patient, to the procedure,
nd the potential morbidity of infection. Antimicrobial pro-
hylaxis is recommended only when the beneﬁts outweigh
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otic and its administration, risk of allergic reactions or other
adverse events, and induction of bacterial resistance).1 Withof antimicrobial prophylaxis and its duration are extremely
important to prevent bacterial resistance induced by unnec-
essary use of antibiotics.
lsevier Editora Ltda. This is an open access article under the CC
.
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Antimicrobial prophylaxis in urologic endoscopic proce-
dures is a controversial topic.2,3 A study published in 2013
evaluating the use of antibiotic prophylaxis in urological pro-
cedures in Europe observed a signiﬁcant discrepancy between
practices in different countries, regions, and hospital proﬁles,
as well as poor adherence to the published recommended
guidelines.4
Detrusor botulinum toxin A injection is an endourologic
procedure which has been widely used for the treatment of
overactivity in patients with neurogenic bladder due to spinal
cord injury who do not respond to conventional treatment.5
The procedure involves injections that penetrate the mucosal
barrier.6
The guidelines of the American and European urological
associations refer to endourologic and transurethral proce-
dures, but do not mention injection of botulinum toxin into
the detrusor.1,7 For these kind of procedures, the main com-
plications are bacteriuria, urinary infection and, more  rarely,
bacteremia and sepsis. Asymptomatic bacteriuria following
endourologic procedures generally has no clinical signiﬁcance
and may spontaneously disappear.5,7,8 A systematic review
that assessed the effectiveness of antimicrobial prophylaxis
in reducing the risk of urinary tract infection in transurethral
urologic procedures evaluated 42 studies, all of which used
the presence of negative urine cultures prior to the proce-
dure as inclusion criteria. Patients with neurogenic bladder
were excluded.9 The only study we  found assessing the need
for antibiotic prophylaxis in patients with neurogenic bladder
for detrusor BoNTA injection included patients with negative
urine cultures before the procedure.10
In the guidelines published by the Infectious Diseases Soci-
ety of America, it is clear that there is no evidence of beneﬁt in
treating asymptomatic bacteriuria. Asymptomatic bacteriuria
(AB) is present in approximately 70% of patients with spinal
cord injury and neurogenic bladder who perform intermittent
bladder catheterization11 due to functional abnormalities, uri-
nary stasis, and the bladder emptying technique. There is an
indication to treat AB only if the patient exhibits clinical symp-
toms of infection.
To assess the beneﬁt of treating asymptomatic bacteriuria
in the prevention of UTI, a retrospective study was conducted
in a rehabilitation hospital, with evaluation of medical records
of patients admitted for detrusor BoNTA injection from Jan-
uary 2007 to December 2013. Patients aged 18 years or older
with traumatic and nontraumatic spinal cord injury, perform-
ing self or assisted clean intermittent bladder catheterization
with a single-use catheter lubricated with 2% xylocaine gel
were included. Urine culture with antibiotic susceptibility test
was performed for all patients in the ﬁrst day of hospital-
ization using midstream urine sample collected by aseptic
bladder catheterization. The exclusion criteria were the appli-
cation of BoNTA into the sphincter or other concomitant
surgical procedure.
Patients were divided into three groups for comparative
analysis, according to the recommendations of the institu-
tional protocol, which guided the management of AB. From
January 2007 to February 2008, the protocol recommended
the use of antibiotics for seven days based on the results of
urine culture, and the urological procedure was performed
on the ﬁfth day of treatment (group 1); from March 2008 to 1 6;2  0(6):623–626
March 2009, the recommendation has changed to the use of
antibiotics for three days with the procedure performed on
the second day of treatment (group 2); from April 2009 to
December 2013, the recommendation was to use a single dose
of antibiotic during anesthetic induction (cefazolin as ﬁrst
option, ciproﬂoxacin as second option) without taking into
account the urine culture (group 3). All patients with nega-
tive urine specimens had a single antibiotic dose, regardless
of the treatment group.
According to the National Institute on Disability and Reha-
bilitation Research quantitative urine-culture criteria for the
diagnosis of asymptomatic bacteriuria included catheter spec-
imens from individuals on intermittent catheterization in
an amount equal to or greater than 102 CFU/mL.11,12 The
criteria for symptomatic urinary tract infection were the pres-
ence of bacteria in catheter specimens from individuals in
an amount equal to or greater than 105 CFU/mL, associated
with at least one of the following clinical symptoms, occur-
ring within 7seven days of the detrusor BoNTA injection13:
fever (temperature greater than or equal to 37.8 ◦C); worsening
of neuropathic pain and/or spasticity; autonomic dysreﬂexia
of unknown cause; increased urine loss between bladder
catheterization; gastric symptoms (nausea, vomiting, loss of
appetite); lower back or suprapubic pain; dysuria; antibiotic
use for treatment of UTI within seven days of the procedure.
Data following discharge were collected through active search-
ing (phone call). Patients were submitted to urine culture 45
days after the procedure, when returning for outpatient eval-
uation.
All patients underwent a rigid cystoscopy under general
or regional anesthesia with sedation and remained hospital-
ized for at least 48 h. The drug used was Botox® (Allergan Inc.,
Irvine, CA, USA), 30 applications of 1 mL  (10 international units
reconstituted with saline), distributed throughout the bladder
excluding the trigone (total dose of 300 IU). All procedures were
performed by the same surgeon.
Demographic data included gender, age and type of injury
(traumatic or nontraumatic). Risk factors investigated were
hematuria and insertion of an indwelling urinary catheter
(IUC) following the procedure, previous diagnosis of Diabetes
mellitus, chronic use of corticosteroids, and smoking. The
information was recorded in a database developed in ACCESS
2003 and analyzed using the statistical package SPSS. Absolute
and relative frequencies were used for categorical variables
and measures of central tendency and dispersion were used
for others. Mann–Whitney or Kruskal–Wallis tests were used
for variables with no normal distribution. Categorical variables
were analyzed using the chi-square test with Yates’ correction,
Fisher’s exact test and the binomial test. p-Values less than 5%
were considered statistically signiﬁcant.
A total of 616 procedures performed during the study
period on 487 patients (1.3 procedures/patient) were evalu-
ated: 332 (68%) were male; the mean age was 37 (±11.6) years;
321 (66%) patients had a traumatic spinal cord injury, and
168 (34%) had a nontraumatic spinal cord injury (Table 1).
Among patients with a traumatic spinal cord injury, 26% had
tetraplegia and 74% had paraplegia and in the group with a
nontraumatic spinal cord injury, the most common conditions
were myelitis (38%), followed by HTLV myelopathy (25%), and
myelomeningocele (10%).
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n  = 104
p-Value
Male, n (%) 227  (66.4) 103 (60.6) 61 (58.7) 0.23a
Mean age (SD) 36.6 (11.1) 37 (11.4) 35.4 (10.7) 0.41b
Traumatic, n (%) 238 (69.6) 106 (62.4) 64 (61.5) 0.14a
Hematuria, n (%) 100 (29.2) 55 (32.4) 38 (36.5) 0.35a
IUC, n (%) 73 (21.3) 49 (28.8) 67 (64.4) <0.05a
Diabetes, n (%) 6 (1.8) 4 (2.4) 4 (3.8) 0.45a
Corticosteroids, n (%) 2 (0.6) 1 (0.6) 1 (1.0) 0.08c
Smoking, n (%) 1 (0.3) 3 (1.8) 0 (0) 0.52c
UTI 5 (1.5) 1 (0.6) 5 (4.8) 0.06d
IUC, indwelling urinary catheter; UTI, urinary tract infection.
a Chi-square test without continuity correction.




































d Likelihood ratio chi-square test.
Most patients (92%) had asymptomatic bacteriuria before
he procedure, while 8% had negative urine cultures. The
ost common bacteria grown from urine specimens taken
efore and after the procedure were Escherichia coli,  followed
y Klebsiella pneumoniae. The prevalence of multidrug resistant
acteria in the urine culture taken before the procedure was
.3%; in the postprocedure exam it was 9.3%.
We observed a difference with respect to the use of
ndwelling urethral catheter (IUC) between the groups, which
as more  common in the group that used antibiotics for more
han three days (p < 0.05). No patient was on corticosteroids or
eclared to smoke in the three study groups (Table 1).
During the study period, 11 cases of symptomatic UTI were
dentiﬁed: ﬁve in the group that treated bacteriuria for more
han three days (4.8%), one in the group that treated for three
ays (0.6%), and ﬁve (1.5%) in the group that received a sin-
le dose. We  detected a trend to higher UTI rates in the group
hat used antibiotics for longer time (≥3 days), in compari-
on with those that used antibiotics for three or less days
p = 0.05). No patient had more  than one symptomatic UTI
vent. The symptoms observed in the patients that developed
 symptomatic UTI were fever and/or chills (81.8%), supra-
ubic pain/discomfort (36.4%), urinary incontinence (27.3%)
nd dysuria (9%). No patient had pyelonephritis, sepsis, or
equired intensive care. We observed no difference between
requency of symptoms for patients with clinical signs of
nfection, regardless of duration of antibiotic use.
In conclusion, the majority of patients in this study had
symptomatic bacteriuria. The study reported 11 cases of
ymptomatic UTI (1.8%) with no difference between the
roups, but with a tendency for a higher rate in the group
hat used more  than three days of antibiotics (p = 0.05). Most
eported clinical symptoms were fever and/or chills. According
o the risk factors, only the insertion of IUCs in patients that
sed antibiotics for more  than three days showed statistical
ifference (p < 0.05).
The ﬁndings of this study are in accordance with previ-
us reports, conﬁrming that patients with spinal cord injury
ho  perform intermittent bladder catheterization have high
ates of asymptomatic bacteriuria.11,14 These patients needto undergo urologic procedures frequently and preventing the
emergence of multidrug-resistant bacteria through rational
use of antibiotics is a priority.15 According to some experts, the
presence of asymptomatic bacteriuria is not a contraindica-
tion for the detrusor BoNTA injection and the use of antibiotic
prophylaxis should follow the normal routine of each hos-
pital site.16 There are studies that show that a single dose
of antimicrobial has been effective and feasible for the pre-
vention of postoperative infection in urological surgery.17 A
study published in 2010,10 with neurological patients with
sterile urine showed a UTI rate of 7.1% in patients who  did not
receive prophylactic antibiotic for detrusor botulinum toxin
injection. Randomized clinical trials suggest higher rates, but
some studies do not distinguish between symptomatic UTI
and asymptomatic bacteriuria. This study describes a low uri-
nary tract infection rate in all treatment groups, suggesting
that a single-dose of antibiotic prevents infection complica-
tions even in patients with asymptomatic bacteriuria.
Risk factors for UTI include advanced age, smoking,
anatomical and functional abnormalities, the use of corti-
costeroids, immunosuppression, and urethral catheters. The
large majority of the patients evaluated in this study had
asymptomatic bacteriuria and the risk factors for UTI were
similar between the groups. The fact that the group that
received antibiotics for more  than three days in this study kept
an IUC in 64.4% after the procedure, may have been related to
the team experience, since we  found that this rate decreased
over the years without relation to complications. The only dif-
ference found between the groups was related to the use of
antimicrobials for longer periods in patients that used an IUC.
In these cases, we found a tendency for statistical difference
in the rates of UTI in comparison to the groups that used
antibiotics for shorter periods of time (p = 0.05), suggesting
that excessive exposure to antibiotics favors the occurrence
of infection. No differences were observed between groups for
the other assessed risk factors.In current practice updates protocols in institutions aimed
at preventing microbial resistance induction generated by
unnecessary use of antibiotics, as well as reducing adverse
reactions, hospitalization time and costs. Because it was a
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non-randomized, retrospective study, the external validity of
these data are limited. Another issue is that the 487 patients
were submitted to 616 interventions, i.e. 20% of patients
approximately participated in more  than one group. The
similarity in the percentage of symptomatic UTI after the pro-
cedure in the three groups may have been due to a population
under similar risk further aggravated by the low incidence of
the outcome (11 in total).
Our results conﬁrm that the use of a single dose of antibi-
otics before the detrusor BoNTA injection in patients with
asymptomatic bacteriuria is enough to prevent symptomatic
UTI. It is necessary to conduct a randomized clinical trial to
assess the effect of different interventions for the manage-
ment of asymptomatic bacteriuria in patients with neurogenic
bladder before detrusor botulinum toxin type A injection.
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